These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 12228826)

  • 1. Human herpesvirus 8-positive Castleman disease in human immunodeficiency virus-infected patients: the impact of highly active antiretroviral therapy.
    Aaron L; Lidove O; Yousry C; Roudiere L; Dupont B; Viard JP
    Clin Infect Dis; 2002 Oct; 35(7):880-2. PubMed ID: 12228826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma HHV-8 viral load in HHV-8-related lymphoproliferative disorders associated with HIV infection.
    Simonelli C; Tedeschi R; Gloghini A; Talamini R; Bortolin MT; Berretta M; Spina M; Morassut S; Vaccher E; De Paoli P; Carbone A; Tirelli U
    J Med Virol; 2009 May; 81(5):888-96. PubMed ID: 19319955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children.
    Sánchez JM; Ramos Amador JT; Fernández de Miguel S; González Tomée MI; Rojo Conejo P; Ferrnado Vivas P; Clemente Vivas J; Ruiz Contreras J; Nogales Espert A
    Pediatr Infect Dis J; 2003 Oct; 22(10):863-7. PubMed ID: 14551485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's disease.
    Hoffmann C; Chow KU; Wolf E; Faetkenheuer G; Stellbrink HJ; van Lunzen J; Jaeger H; Stoehr A; Plettenberg A; Wasmuth JC; Rockstroh J; Mosthaf F; Horst HA; Brodt HR
    Br J Haematol; 2004 May; 125(4):455-62. PubMed ID: 15142115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial human herpesvirus-8 rash and multicentric Castleman disease.
    Wyplosz B; Carlotti A; Escaut L; Vignier N; Guettier C; Agbalika F; Vittecoq D; Dupin N
    Clin Infect Dis; 2008 Sep; 47(5):684-8. PubMed ID: 18652555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Castlemans disease in HIV infected patient from eastern India.
    Modak D; Ganguly RR; Haldar SN; Samanta PS; Pramanik N; Guha SK
    J Assoc Physicians India; 2008 Jul; 56():547-8. PubMed ID: 18846911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma.
    Bihl F; Mosam A; Henry LN; Chisholm JV; Dollard S; Gumbi P; Cassol E; Page T; Mueller N; Kiepiela P; Martin JN; Coovadia HM; Scadden DT; Brander C
    AIDS; 2007 Jun; 21(10):1245-52. PubMed ID: 17545700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fatal immune restoration disease in human immunodeficiency virus type 1-infected patients with progressive multifocal leukoencephalopathy: impact of antiretroviral therapy-associated immune reconstitution.
    Safdar A; Rubocki RJ; Horvath JA; Narayan KK; Waldron RL
    Clin Infect Dis; 2002 Nov; 35(10):1250-7. PubMed ID: 12410486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up.
    Phillips P; Bonner S; Gataric N; Bai T; Wilcox P; Hogg R; O'Shaughnessy M; Montaner J
    Clin Infect Dis; 2005 Nov; 41(10):1483-97. PubMed ID: 16231262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency of visceral leishmaniasis relapses in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy.
    Mira JA; Corzo JE; Rivero A; Macias J; De Leon FL; Torre-Cisneros J; Gomez-Mateos J; Jurado R; Pineda JA
    Am J Trop Med Hyg; 2004 Mar; 70(3):298-301. PubMed ID: 15031520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Failure of rituximab in human immunodeficiency virus-associated multicentric Castleman disease.
    Neuville S; Agbalika F; Rabian C; Brière J; Molina JM
    Am J Hematol; 2005 Aug; 79(4):337-9. PubMed ID: 16044438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
    Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Van Dyke RB; Seage GR;
    Clin Infect Dis; 2008 Feb; 46(4):507-15. PubMed ID: 18199042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
    Wang C; Vlahov D; Galai N; Bareta J; Strathdee SA; Nelson KE; Sterling TR
    J Infect Dis; 2004 Sep; 190(6):1046-54. PubMed ID: 15319852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion.
    Miailhes P; Trabaud MA; Pradat P; Lebouché B; Chevallier M; Chevallier P; Zoulim F; Trepo C
    Clin Infect Dis; 2007 Sep; 45(5):624-32. PubMed ID: 17682999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy.
    Tedaldi EM; Baker RK; Moorman AC; Alzola CF; Furhrer J; McCabe RE; Wood KC; Holmberg SD;
    Clin Infect Dis; 2003 Feb; 36(3):363-7. PubMed ID: 12539079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in mortality related to human immunodeficiency virus infection: comparative analysis of inpatient deaths in 1995 and in 1999-2000.
    Jain MK; Skiest DJ; Cloud JW; Jain CL; Burns D; Berggren RE
    Clin Infect Dis; 2003 Apr; 36(8):1030-8. PubMed ID: 12684916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral lesions as clinical markers of highly active antiretroviral therapy failure: a nested case-control study in Mexico City.
    Ramírez-Amador V; Ponce-de-León S; Anaya-Saavedra G; Crabtree Ramírez B; Sierra-Madero J
    Clin Infect Dis; 2007 Oct; 45(7):925-32. PubMed ID: 17806063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low rates of antiretroviral therapy among HIV-infected patients with chronic kidney disease.
    Choi AI; Rodriguez RA; Bacchetti P; Volberding PA; Havlir D; Bertenthal D; Bostrom A; O'Hare AM
    Clin Infect Dis; 2007 Dec; 45(12):1633-9. PubMed ID: 18190326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.